{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:52:08Z","timestamp":1790628728308,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003261"],"award-info":[{"award-number":["82003261"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Henan Provincial Science and Technology Research and Development Joint Fund","award":["235101610047"],"award-info":[{"award-number":["235101610047"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08542-y","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:17:09Z","timestamp":1783523829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Engineered PD1-NKG2D Dual-CAR NK92 cells broaden antitumor target recognition in preclinical tumor models"],"prefix":"10.1186","volume":"24","author":[{"given":"Xinru","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingtong","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norfarazieda","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"8542_CR1","doi-asserted-by":"publisher","first-page":"e2443198","DOI":"10.1001\/jamanetworkopen.2024.43198","volume":"7","author":"HM Bizuayehu","year":"2024","unstructured":"Bizuayehu HM, Ahmed KY, Kibret GD, Dadi AF, Belachew SA, Bagade T, Tegegne TK, Venchiarutti RL, Kibret KT, Hailegebireal AH, et al. Global Disparities of Cancer and Its Projected Burden in 2050. JAMA Netw Open. 2024;7:e2443198.","journal-title":"JAMA Netw Open"},{"key":"8542_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175\u201396.","journal-title":"Nat Rev Drug Discov"},{"key":"8542_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"8542_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.tips.2024.07.005","volume":"45","author":"YR Li","year":"2024","unstructured":"Li YR, Lyu Z, Chen Y, Fang Y, Yang L. Frontiers in CAR-T cell therapy for autoimmune diseases. Trends Pharmacol Sci. 2024;45:839\u201357.","journal-title":"Trends Pharmacol Sci"},{"key":"8542_CR5","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21:1089\u2013108.","journal-title":"Cell Mol Immunol"},{"key":"8542_CR6","doi-asserted-by":"crossref","unstructured":"Kong Y, Li J, Zhao X, Wu Y, Chen L. CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity. Front Immunol 2025:15.","DOI":"10.3389\/fimmu.2024.1519671"},{"key":"8542_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399.","journal-title":"Nat Rev Drug Discov"},{"key":"8542_CR8","doi-asserted-by":"publisher","first-page":"822298","DOI":"10.3389\/fimmu.2022.822298","volume":"13","author":"KE Ruppel","year":"2022","unstructured":"Ruppel KE, Fricke S, Kohl U, Schmiedel D. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy. Front Immunol. 2022;13:822298.","journal-title":"Front Immunol"},{"key":"8542_CR9","doi-asserted-by":"crossref","unstructured":"Yang N, Zhang C, Zhang Y, Fan Y, Zhang J, Lin X, Guo T, Gu Y, Wu J, Gao J et al. CD19\/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia. J Translational Med 2024:22.","DOI":"10.1186\/s12967-024-04990-6"},{"key":"8542_CR10","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","volume":"31","author":"L Tang","year":"2023","unstructured":"Tang L, Pan S, Wei X, Xu X, Wei Q. Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development. Mol Ther. 2023;31:3146\u201362.","journal-title":"Mol Ther"},{"key":"8542_CR11","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41409-025-02679-y","volume":"60","author":"M Gomez-Llobell","year":"2025","unstructured":"Gomez-Llobell M, Serra Smith C, Gomez-Costas D, Gomez-Centurion I, Garcia Dominguez JM, Escudero-Vilaplana V, Fernandez Bullido Y, Carbonell D, Pion M, Bailen R, et al. ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling. Bone Marrow Transpl. 2025;60:1351\u201360.","journal-title":"Bone Marrow Transpl"},{"key":"8542_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14:73.","journal-title":"J Hematol Oncol"},{"key":"8542_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","volume":"14","author":"S Liu","year":"2021","unstructured":"Liu S, Galat V, Galat Y, Lee YKA, Wainwright D, Wu J. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021;14:7.","journal-title":"J Hematol Oncol"},{"key":"8542_CR14","doi-asserted-by":"publisher","first-page":"673276","DOI":"10.3389\/fonc.2021.673276","volume":"11","author":"F Marofi","year":"2021","unstructured":"Marofi F, Al-Awad AS, Sulaiman Rahman H, Markov A, Abdelbasset WK, Ivanovna Enina Y, Mahmoodi M, Hassanzadeh A, Yazdanifar M, Stanley Chartrand M, Jarahian M. CAR-NK Cell: A New Paradigm in Tumor Immunotherapy. Front Oncol. 2021;11:673276.","journal-title":"Front Oncol"},{"key":"8542_CR15","doi-asserted-by":"publisher","first-page":"e1274","DOI":"10.1002\/cti2.1274","volume":"10","author":"M Daher","year":"2021","unstructured":"Daher M, Melo Garcia L, Li Y, Rezvani K. CAR-NK cells: the next wave of cellular therapy for cancer. Clin Transl Immunol. 2021;10:e1274.","journal-title":"Clin Transl Immunol"},{"key":"8542_CR16","doi-asserted-by":"crossref","unstructured":"J\u00f8rgensen LV, Christensen EB, Barnkob MB, Barington T. The clinical landscape of CAR NK cells. Experimental Hematol Oncol 2025:14.","DOI":"10.1186\/s40164-025-00633-8"},{"key":"8542_CR17","doi-asserted-by":"publisher","first-page":"115123","DOI":"10.1016\/j.biopha.2023.115123","volume":"165","author":"X Lin","year":"2023","unstructured":"Lin X, Sun Y, Dong X, Liu Z, Sugimura R, Xie G. IPSC-derived CAR-NK cells for cancer immunotherapy. Biomed Pharmacother. 2023;165:115123.","journal-title":"Biomed Pharmacother"},{"key":"8542_CR18","doi-asserted-by":"publisher","first-page":"886429","DOI":"10.3389\/fimmu.2022.886429","volume":"13","author":"F Rossi","year":"2022","unstructured":"Rossi F, Fredericks N, Snowden A, Allegrezza MJ, Moreno-Nieves UY. Next Generation Natural Killer Cells for Cancer Immunotherapy. Front Immunol. 2022;13:886429.","journal-title":"Front Immunol"},{"key":"8542_CR19","doi-asserted-by":"publisher","first-page":"732135","DOI":"10.3389\/fimmu.2021.732135","volume":"12","author":"EL Heipertz","year":"2021","unstructured":"Heipertz EL, Zynda ER, Stav-Noraas TE, Hungler AD, Boucher SE, Kaur N, Vemuri MC. Current Perspectives on Off-The-Shelf Allogeneic NK and CAR-NK Cell Therapies. Front Immunol. 2021;12:732135.","journal-title":"Front Immunol"},{"key":"8542_CR20","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","volume":"59","author":"G Xie","year":"2020","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975.","journal-title":"EBioMedicine"},{"key":"8542_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12943-025-02277-y","volume":"24","author":"H Wang","year":"2025","unstructured":"Wang H, Sun P, Yuan X, Xu Z, Jiang X, Xiao M, Yao X, Shi Y. Autophagy in tumor immune escape and immunotherapy. Mol Cancer. 2025;24:85.","journal-title":"Mol Cancer"},{"key":"8542_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","volume":"10","author":"W Wang","year":"2024","unstructured":"Wang W, Liu Y, He Z, Li L, Liu S, Jiang M, Zhao B, Deng M, Wang W, Mi X, et al. Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discov. 2024;10:40.","journal-title":"Cell Death Discov"},{"key":"8542_CR23","doi-asserted-by":"publisher","first-page":"124558","DOI":"10.1016\/j.ijpharm.2024.124558","volume":"663","author":"C Liu","year":"2024","unstructured":"Liu C, Wang Q, Li L, Gao F, Zhang Y, Zhu Y. The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy. Int J Pharm. 2024;663:124558.","journal-title":"Int J Pharm"},{"key":"8542_CR24","doi-asserted-by":"publisher","first-page":"113166","DOI":"10.1016\/j.intimp.2024.113166","volume":"142","author":"H Sima","year":"2024","unstructured":"Sima H, Shao W. Advancements in the design and function of bispecific CAR-T cells targeting B Cell-Associated tumor antigens. Int Immunopharmacol. 2024;142:113166.","journal-title":"Int Immunopharmacol"},{"key":"8542_CR25","doi-asserted-by":"publisher","first-page":"5944","DOI":"10.1038\/onc.2008.272","volume":"27","author":"N Nausch","year":"2008","unstructured":"Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene. 2008;27:5944\u201358.","journal-title":"Oncogene"},{"key":"8542_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fimmu.2015.00097","volume":"6","author":"J Zhang","year":"2015","unstructured":"Zhang J, Basher F, Wu JD. NKG2D Ligands in Tumor Immunity: Two Sides of a Coin. Front Immunol. 2015;6:97.","journal-title":"Front Immunol"},{"key":"8542_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0969-2126(03)00047-9","volume":"11","author":"BJ McFarland","year":"2003","unstructured":"McFarland BJ, Kortemme T, Yu SF, Baker D, Strong RK. Symmetry recognizing asymmetry: analysis of the interactions between the C-type lectin-like immunoreceptor NKG2D and MHC class I-like ligands. Structure. 2003;11:411\u201322.","journal-title":"Structure"},{"key":"8542_CR28","doi-asserted-by":"publisher","first-page":"1763843","DOI":"10.3389\/fimmu.2026.1763843","volume":"17","author":"C Liu","year":"2026","unstructured":"Liu C, Wang Z, Zhang W, Cheng G, Cheng S, Qin L, Ye H, Ren W. NKG2D CAR-T cells for solid tumor immunotherapy: advances, challenges, and future directions. Front Immunol. 2026;17:1763843.","journal-title":"Front Immunol"},{"key":"8542_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2018.02.004","volume":"51","author":"P Dhar","year":"2018","unstructured":"Dhar P, Wu JD. NKG2D and its ligands in cancer. Curr Opin Immunol. 2018;51:55\u201361.","journal-title":"Curr Opin Immunol"},{"key":"8542_CR30","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3389\/fimmu.2019.00661","volume":"10","author":"A Frazao","year":"2019","unstructured":"Frazao A, Rethacker L, Messaoudene M, Avril MF, Toubert A, Dulphy N, Caignard A. NKG2D\/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment. Front Immunol. 2019;10:661.","journal-title":"Front Immunol"},{"key":"8542_CR31","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/14737167.2019.1651646","volume":"19","author":"P Petrou","year":"2019","unstructured":"Petrou P. Is it a Chimera? A systematic review of the economic evaluations of CAR-T cell therapy. Expert Rev Pharmacoecon Outcomes Res. 2019;19:529\u201336.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"8542_CR32","first-page":"314","volume":"3","author":"E von Pogge","year":"2015","unstructured":"von Pogge E, Shatnyeva O, Hansen HP. NKp30 and its ligands: emerging players in tumor immune evasion from natural killer cells. Ann Transl Med. 2015;3:314.","journal-title":"Ann Transl Med"},{"key":"8542_CR33","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170:1109\u2013e11191110.","journal-title":"Cell"},{"key":"8542_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","volume":"8","author":"H Jiang","year":"2014","unstructured":"Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F, Zeng T, Huang H, Zhang X, Sun W, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol. 2014;8:297\u2013310.","journal-title":"Mol Oncol"},{"key":"8542_CR35","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","volume":"19","author":"LB John","year":"2013","unstructured":"John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19:5636\u201346.","journal-title":"Clin Cancer Res"},{"key":"8542_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18:10.","journal-title":"Mol Cancer"},{"key":"8542_CR37","doi-asserted-by":"publisher","first-page":"e28497","DOI":"10.4161\/onci.28497","volume":"3","author":"A Baragano Raneros","year":"2014","unstructured":"Baragano Raneros A, Suarez-Alvarez B, Lopez-Larrea C. Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention. Oncoimmunology. 2014;3:e28497.","journal-title":"Oncoimmunology"},{"key":"8542_CR38","doi-asserted-by":"publisher","first-page":"e1323618","DOI":"10.1080\/2162402X.2017.1323618","volume":"6","author":"C Maccalli","year":"2017","unstructured":"Maccalli C, Giannarelli D, Chiarucci C, Cutaia O, Giacobini G, Hendrickx W, Amato G, Annesi D, Bedognetti D, Altomonte M, et al. Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. Oncoimmunology. 2017;6:e1323618.","journal-title":"Oncoimmunology"},{"key":"8542_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-017-0444-9","volume":"10","author":"S Yu","year":"2017","unstructured":"Yu S, Li A, Liu Q, Li T, Yuan X, Han X, Wu K. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol. 2017;10:78.","journal-title":"J Hematol Oncol"},{"key":"8542_CR40","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"8542_CR41","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"8542_CR42","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med. 2017;377:2545\u201354.","journal-title":"N Engl J Med"},{"key":"8542_CR43","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s11684-019-0714-8","volume":"13","author":"H Chen","year":"2019","unstructured":"Chen H, Wang F, Zhang P, Zhang Y, Chen Y, Fan X, Cao X, Liu J, Yang Y, Wang B, et al. Management of cytokine release syndrome related to CAR-T cell therapy. Front Med. 2019;13:610\u20137.","journal-title":"Front Med"},{"key":"8542_CR44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan T, Zhu L, Chen J. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 2023;12:14.","journal-title":"Exp Hematol Oncol"},{"key":"8542_CR45","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, Weng J, Du X, Wu K, Lai P. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol. 2024;17:105.","journal-title":"J Hematol Oncol"},{"key":"8542_CR46","doi-asserted-by":"publisher","first-page":"713158","DOI":"10.3389\/fimmu.2021.713158","volume":"12","author":"MB Fuertes","year":"2021","unstructured":"Fuertes MB, Domaica CI, Zwirner NW. Leveraging NKG2D Ligands in Immuno-Oncology. Front Immunol. 2021;12:713158.","journal-title":"Front Immunol"},{"key":"8542_CR47","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederstadt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022;22:557\u201375.","journal-title":"Nat Rev Cancer"},{"key":"8542_CR48","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.coi.2018.03.013","volume":"51","author":"M Daher","year":"2018","unstructured":"Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol. 2018;51:146\u201353.","journal-title":"Curr Opin Immunol"},{"key":"8542_CR49","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.3389\/fimmu.2017.01846","volume":"8","author":"G Huang","year":"2017","unstructured":"Huang G, Liu X, Duszynski DW, Tang X, El-Ashram S, Liu Z, Suo X, Li Q. Improved Cytotoxic T Lymphocyte Responses to Vaccination with Porcine Reproductive and Respiratory Syndrome Virus in 4-1BB Transgenic Pigs. Front Immunol. 2017;8:1846.","journal-title":"Front Immunol"},{"key":"8542_CR50","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19:200\u201318.","journal-title":"Nat Rev Drug Discov"},{"key":"8542_CR51","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.bbmt.2015.12.028","volume":"22","author":"BC Shaffer","year":"2016","unstructured":"Shaffer BC, Le Luduec JB, Forlenza C, Jakubowski AA, Perales MA, Young JW, Hsu KC. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2016;22:705\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"8542_CR52","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","volume":"65","author":"G Suck","year":"2016","unstructured":"Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, Tonn T. NK-92: an \u2018off-the-shelf therapeutic\u2019 for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother. 2016;65:485\u201392.","journal-title":"Cancer Immunol Immunother"},{"key":"8542_CR53","doi-asserted-by":"crossref","unstructured":"Duan S, Guo W, Xu Z, He Y, Liang C, Mo Y, Wang Y, Xiong F, Guo C, Li Y et al. Natural killer group 2D receptor and its ligands in cancer immune escape. Mol Cancer 2019:18.","DOI":"10.1186\/s12943-019-0956-8"},{"key":"8542_CR54","doi-asserted-by":"crossref","unstructured":"Martinez M, Moon EK. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol 2019:10.","DOI":"10.3389\/fimmu.2019.00128"},{"key":"8542_CR55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"8542_CR56","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","volume":"68","author":"K Newick","year":"2017","unstructured":"Newick K, O\u2019Brien S, Moon E, Albelda SM. CAR T Cell Therapy for Solid Tumors. Annu Rev Med. 2017;68:139\u201352.","journal-title":"Annu Rev Med"},{"key":"8542_CR57","doi-asserted-by":"crossref","unstructured":"Satapathy BP, Sheoran P, Yadav R, Chettri D, Sonowal D, Dash CP, Dhaka P, Uttam V, Yadav R, Jain M, Jain A. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review. Front Immunol 2024:15.","DOI":"10.3389\/fimmu.2024.1389971"},{"key":"8542_CR58","doi-asserted-by":"publisher","first-page":"138","DOI":"10.33086\/ijmlst.v7i2.7711","volume":"7","author":"IGPA Wedharga","year":"2025","unstructured":"Wedharga IGPA, Willianto VM, Theodora I, Parengkuan I, Novita BD. STAT3, but not Ki-67, expression is independently associated with tumor progression in colorectal carcinoma: A comparative immunohistochemical biomarker analysis. Indonesian J Med Lab Sci Technol. 2025;7:138\u201347.","journal-title":"Indonesian J Med Lab Sci Technol"},{"key":"8542_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.33086\/ijmlst.v4i1.2355","volume":"4","author":"SE Pratiwi","year":"2022","unstructured":"Pratiwi SE, Wahyuningrum SN, Putri RP, Danarto D, Heriyanto DS, Arfian N, Haryana SM, Astuti I. MiR-141-3p Relative Expression Level from FFPE Samples as Biomarker of Prostate Adenocarcinoma Carcinogenesis in Yogyakarta, Indonesia. Indonesian J Med Lab Sci Technol. 2022;4:1\u20139.","journal-title":"Indonesian J Med Lab Sci Technol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08542-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08542-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08542-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T13:18:51Z","timestamp":1786108731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08542-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8542"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08542-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Henan Medical University and were performed in accordance with institutional guidelines and the ARRIVE guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors approved the contents of the manuscript and agreed with the publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1016"}}